Retension Pharmaceuticals Inc

RTSNHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

12.150.00 (0.00%)

2026-11-12 13:52 CET

Market cap

101.23 USD m

Revenue, TTM

0.00 USD m

Net income, TTM

-4.17 USD m

Free cash flow, TTM

-2.80 USD m

EPS diluted, TTM

-0.53

P/E

Compare

Price

RTSN against its 20-day averages

Patternshover a marker to name it

EPS mean, own scale

34.8% under the 52-week high of 18.64 on 19 Oct 2026. 52-week low 9.66 on 9 Oct 2026. Last 15 sessions, 58.0% high to low

Volume 0.00× normal · the session has not printed · the line is the 50-bar volume average

Profile

RTSN

52-week range, 28% of the way up

9.6618.64

Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. The company was founded by Eric Keller and Paul Sweetnam in 2023 and is headquartered in Falls Church, VA.

IPO	Oct 09, 2026
ATR, 14d	1.75
Rel volume	0.00
Short float	1.08%
Insider own	23.62%
Inst own	22.03%

Snapshot

6 groups

Valuation

Index	-
Market Cap	101.23M
Enterprise Value	115.91M
Income	-
Sales	-
Book/sh	-1.89
Cash/sh	1.62
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Oct 09, 2026

Ratios

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	7.50
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	5.61
Current Ratio	5.61
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

Earnings

EPS (ttm)	-
EPS next Y	-
EPS next Q	-0.49
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Sep 02
EPS/Sales Surpr.	- -

Ownership

Insider Own	23.62%
Insider Trans	1.59%
Inst Own	22.03%
Inst Trans	60.59%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-7.10%
SMA50	-4.92%
SMA200	-4.92%
Trades	-

Technical

Shs Outstand	7.88M
Shs Float	6.36M
Short Float	1.08%
Short Ratio	0.46
Short Interest	0.07M
52W High	18.64 -34.82%
52W Low	9.66 25.78%
Volatility	13.30% 14.98%
ATR (14)	1.75
RSI (14)	56.09
Beta	-
Rel Volume	0.00
Avg Volume	149.45K
Volume	0

Performance

Perf Week	4.79%
Perf Month	4.47%
Perf Quarter	-
Perf Half Y	-
Perf YTD	21.50%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	51.67
Prev Close	12.15
Price	12.15
Change %	0.00%

Peers

Mkt cap

Ticker	Company	Mkt cap
MLYS	Mineralys Therapeutics Inc	1.42B
TENX	Tenax Therapeutics Inc	75.59M
KARD	Kardigan Inc	1.47B
MIST	Milestone Pharmaceuticals Inc	88.09M
NAMS	NewAmsterdam Pharma Company NV	2.47B
GOSS	Gossamer Bio Inc	69.73M
CVKD	Cadrenal Therapeutics Inc	5.24M
CRDL	Cardiol Therapeutics Inc	121.87M
CYTK	Cytokinetics Inc	8.22B
LQDA	Liquidia Corp	4.96B

Ticker

Company

Mkt cap

MLYS

Mineralys Therapeutics Inc

1.42B

TENX

Tenax Therapeutics Inc

75.59M

KARD

Kardigan Inc

1.47B

MIST

Milestone Pharmaceuticals Inc

88.09M

NAMS

NewAmsterdam Pharma Company NV

2.47B

GOSS

Gossamer Bio Inc

69.73M

CVKD

Cadrenal Therapeutics Inc

5.24M

CRDL

Cardiol Therapeutics Inc

121.87M

CYTK

Cytokinetics Inc

8.22B

LQDA

Liquidia Corp

4.96B

Insider trading

2 filings

Insider	Relationship	Date	Transaction	Cost	Shares	Value	Total held	Form
Keller Eric L.	CHIEF EXECUTIVE OFFICER	Oct 13 '26	Buy	12.00	20,800	249,600	423,377	Oct 13 06:12 PM
BERGER FRANKLIN M	Director	Oct 13 '26	Buy	12.00	10,000	120,000	10,000	Oct 13 06:10 PM

Key figures

Revenue, TTM	0.00
Net income, TTM	-4.17
EPS diluted, TTM	-0.53
EBIT, TTM	-4.29
Free cash flow, TTM	-2.80
Gross margin	-%
Operating margin	-%
Net margin	-%
Market cap	101.23
P/E	-
Sales Y/Y, TTM	-

USD millions. TTM from the statement feed.

Quarterly earnings

actual against estimate

Period	Reported	EPS act	EPS est	EPS rep	Sales act	Sales est	Analysts
2026Q2	2026-09-02	-0.750	-	-	0.00	-	-
2026Q3	-	-	-0.490	-	-	0.00	1
2026Q4	-	-	-0.580	-	-	0.00	1

Annual earnings

Period	EPS act	EPS est	EPS rep	Sales act	Sales est
No annual earnings.

Period

EPS act

EPS est

EPS rep

Sales act

Sales est

No annual earnings.

Estimate revisions

last 14 periods

Period	Type	Date	Estimates	Up	Down	Mean	Low	High
2026Q3	S	2026-11-02	1	0	0	0.00	0.00	0.00
2026Q3	E	2026-11-02	1	0	0	-0.49	-0.49	-0.49

Estimate history

Period	2024	2025
EPS, annual	-0.242	-1.092
EPS, quarterly	-0.083	-0.156	-0.426	-0.529
Period	Q1 '25	Q2 '25	Q1 '26	Q2 '26
Sales, annual	0	0
Period	2024	2025
Sales, quarterly	0	0	0	0
Period	Q1 '25	Q2 '25	Q1 '26	Q2 '26
Shares, annual	7.882	7.882	7.882
Period	2024	2025	MRQ
Shares, quarterly	7.882	7.882	7.882	7.882
Period	Q1 '25	Q2 '25	Q1 '26	Q2 '26

Income statement, annual

Currency USD, millions
Metric	TTM	2025FY	2024FY
Total Revenue	0.00	0.00	0.00
Cost of Goods Sold Incl. D&A	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00
Selling, General and Administrative Excl. Other	4.29	9.18	2.28
Research and Development	3.44	7.41	1.30
Other Operating Expense	0.00	0.00	0.00
Operating Income	-4.29	-9.18	-2.28
Unusual Expense	0.00	0.00	-0.02
Net Income Before Taxes	-4.17	-8.61	-1.91
Income Taxes	0.00	0.00	0.00
Consolidated Net Income	-4.17	-8.61	-1.91
Net Income From Continuing Operations	-4.17	-8.61	-1.91
Net Income	-4.17	-8.61	-1.91
EPS (Recurring)	-0.53	-1.09	-0.24
EPS (Basic, Before Extraordinaries)	-0.53	-1.09	-0.24
EPS (Diluted)	-0.53	-1.09	-0.24
EBITDA	-4.29	-9.18	-2.28
Non-Operating Income (Expense)	0.12	0.58	0.36
Other After Tax Adjustments	0.00	0.00	0.00
Stock Option Compensation Expense	0.15	0.25	0.14
Shares Outstanding	7.88	7.88	7.88
Market Capitalization	101.23	101.23	-

Income statement, quarterly

Currency USD, millions
Metric	2026Q2	2026Q1	2025Q2	2025Q1
Total Revenue	0.00	0.00	0.00	0.00
Cost of Goods Sold Incl. D&A	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00
Selling, General and Administrative Excl. Other	4.29	3.50	1.38	0.73
Research and Development	3.44	2.76	0.80	0.38
Other Operating Expense	0.00	0.00	0.00	0.00
Operating Income	-4.29	-3.50	-1.38	-0.73
Unusual Expense	0.00	0.00	0.00	0.00
Net Income Before Taxes	-4.17	-3.35	-1.23	-0.66
Income Taxes	0.00	0.00	0.00	0.00
Consolidated Net Income	-4.17	-3.35	-1.23	-0.66
Net Income From Continuing Operations	-4.17	-3.35	-1.23	-0.66
Net Income	-4.17	-3.35	-1.23	-0.66
EPS (Recurring)	-0.53	-0.43	-0.16	-0.08
EPS (Basic, Before Extraordinaries)	-0.53	-0.43	-0.16	-0.08
EPS (Diluted)	-0.53	-0.43	-0.16	-0.08
EBITDA	-4.29	-3.50	-1.38	-0.73
Non-Operating Income (Expense)	0.12	0.14	0.15	0.08
Other After Tax Adjustments	0.00	0.00	0.00	0.00
Stock Option Compensation Expense	0.15	0.09	0.03	0.03
Shares Outstanding	7.88	7.88	7.88	7.88
Market Capitalization	101.23	-	-	-

Balance sheet, annual

Currency USD, millions
Metric	2025FY	2024FY
Cash & Short Term Investments	18.90	8.19
Short Term Receivables	0.00	0.00
Inventories	0.00	0.00
Other Current Assets	0.24	0.18
Total Current Assets	19.14	8.37
Net Property, Plant & Equipment	0.00	0.00
Total Investments and Advances	0.00	0.00
Intangible Assets	0.00	0.00
Other Assets	0.00	0.00
Total Assets	19.14	8.37
Short Term Debt Incl. Current Port. of LT Debt	0.00	0.00
Accounts Payable	0.00	0.00
Other Current Liabilities	0.91	0.28
Total Current Liabilities	0.91	0.28
Long Term Debt	28.32	9.82
Provision for Risks Charges	0.00	0.00
Other Liabilities	0.00	0.00
Total Liabilities	29.23	10.10
Non-Equity Reserves	0.00	0.00
Preferred Stock - Carrying Value	0.00	0.00
Common Equity	-10.09	-1.73
Total Shareholders Equity	-10.09	-1.73
Accumulated Minority Interest	0.00	0.00
Total Equity	-10.09	-1.73
Total Liabilities & Stockholders Equity	19.14	8.37
Book Value Per Share	-1.28	-0.22
Tangible Book Value Per Share	-1.28	-0.22
Price to Book Ratio	-6.42	-
Return on Assets	-62.56	-
Return on Invested Capital	-47.21	-23.60
Quick Ratio	20.98	30.22
Current Ratio	20.98	30.22

Cash flow, annual

Currency USD, millions
Metric	TTM	2025FY	2024FY
Net Income	-4.17	-8.61	-1.91
Other Funds (Non Cash)	0.15	0.25	0.13
Funds from Operations	-4.02	-8.36	-1.78
Extraordinary Item	0.00	0.00	0.00
Changes in Working Capital	1.22	0.58	0.03
Cash from Operating Activities	-2.80	-7.78	-1.76
Capital Expenditures	0.00	0.00	0.00
Net Assets From Acquisitions	0.00	0.00	0.00
Sale of Fixed Assets and Businesses	0.00	0.00	0.00
Purchase or Sale of Investments	0.00	0.00	0.00
Purchase of Investments	0.00	0.00	0.00
Sale Or Maturity of Investments	0.00	0.00	0.00
Other Uses	0.00	0.00	0.00
Other Sources	0.00	0.00	0.00
Cash from Investing Activities	0.00	0.00	0.00
Cash Dividends Paid	0.00	0.00	0.00
Preferred Dividends (Cash Flow)	0.00	0.00	0.00
Change in Capital Stock	0.00	18.50	3.61
Repurchase of Common Pref Stock	0.00	0.00	0.00
Sale of Common Pref Stock	0.00	18.50	3.61
Proceedsfrom Stock Options	0.00	18.50	3.61
Issuance or Reduction of Debt, Net	0.00	0.00	0.00
Change in Long Term Debt	0.00	0.00	0.00
Issuance of Long Term Debt	0.00	0.00	0.00
Reduction of Long Term Debt	0.00	0.00	0.00
Net Financing Active Other Cash Flow	0.00	0.00	0.00
Other Financing Activities Uses	0.00	0.00	0.00
Cash from Financing Activities	0.00	18.50	3.61
Net Change in Cash	-2.80	10.72	1.86
Free Cash Flow	-2.80	-7.78	-1.76
Deferred Taxes & Investment Tax Credit	-	0.00	0.00

Balance sheet, quarterly

Currency USD, millions
Metric	2026Q2	2026Q1	2025Q2	2025Q1
Cash & Short Term Investments	13.49	16.29	-	-
Short Term Receivables	0.00	0.00	-	-
Inventories	0.00	0.00	-	-
Other Current Assets	2.63	0.32	-	-
Total Current Assets	16.13	16.61	-	-
Net Property, Plant & Equipment	0.00	0.00	-	-
Total Investments and Advances	0.00	0.00	-	-
Intangible Assets	0.00	0.00	-	-
Other Assets	0.00	0.00	-	-
Total Assets	16.13	16.61	-	-
Short Term Debt Incl. Current Port. of LT Debt	0.00	0.00	-	-
Accounts Payable	0.00	0.00	-	-
Other Current Liabilities	2.88	1.64	-	-
Total Current Liabilities	2.88	1.64	-	-
Long Term Debt	28.17	28.17	-	-
Provision for Risks Charges	0.00	0.00	-	-
Other Liabilities	0.00	0.00	-	-
Total Liabilities	31.05	29.81	-	-
Non-Equity Reserves	0.00	0.00	-	-
Preferred Stock - Carrying Value	0.00	0.00	-	-
Common Equity	-14.92	-13.20	-	-
Total Shareholders Equity	-14.92	-13.20	-	-
Accumulated Minority Interest	0.00	0.00	-	-
Total Equity	-14.92	-13.20	-	-
Total Liabilities & Stockholders Equity	16.13	16.61	-	-
Book Value Per Share	-1.89	-1.68	-	-
Tangible Book Value Per Share	-1.89	-1.68	-	-
Price to Book Ratio	-6.42	-	-	-
Return on Invested Capital	-31.47	-22.41	-	-
Quick Ratio	5.61	10.14	-	-
Current Ratio	5.61	10.14	-	-

Cash flow, quarterly

Currency USD, millions
Metric	2026Q2	2026Q1	2025Q2	2025Q1
Net Income	-4.17	-3.35	-1.23	-0.66
Other Funds (Non Cash)	0.15	0.09	0.18	0.03
Funds from Operations	-4.02	-3.26	-1.05	-0.62
Extraordinary Item	0.00	0.00	0.00	0.00
Changes in Working Capital	1.22	0.65	0.47	-0.11
Cash from Operating Activities	-2.80	-2.61	-0.57	-0.73
Capital Expenditures	0.00	0.00	0.00	0.00
Net Assets From Acquisitions	0.00	0.00	0.00	0.00
Sale of Fixed Assets and Businesses	0.00	0.00	0.00	0.00
Purchase or Sale of Investments	0.00	0.00	0.00	0.00
Purchase of Investments	0.00	0.00	0.00	0.00
Sale Or Maturity of Investments	0.00	0.00	0.00	0.00
Other Uses	0.00	0.00	0.00	0.00
Other Sources	0.00	0.00	0.00	0.00
Cash from Investing Activities	0.00	0.00	0.00	0.00
Cash Dividends Paid	0.00	0.00	0.00	0.00
Preferred Dividends (Cash Flow)	0.00	0.00	0.00	0.00
Change in Capital Stock	0.00	0.00	11.37	0.00
Repurchase of Common Pref Stock	0.00	0.00	0.00	0.00
Sale of Common Pref Stock	0.00	0.00	11.37	0.00
Proceedsfrom Stock Options	0.00	-0.00	11.37	0.00
Issuance or Reduction of Debt, Net	0.00	0.00	0.00	0.00
Change in Long Term Debt	0.00	0.00	0.00	0.00
Issuance of Long Term Debt	0.00	0.00	0.00	0.00
Reduction of Long Term Debt	0.00	0.00	0.00	0.00
Net Financing Active Other Cash Flow	0.00	0.00	0.00	0.00
Other Financing Activities Uses	0.00	0.00	0.00	0.00
Cash from Financing Activities	0.00	0.00	11.37	0.00
Net Change in Cash	-2.80	-2.61	10.80	-0.73
Free Cash Flow	-2.80	-2.61	-0.57	-0.73

Revenue breakdown

Revenue split	-

Short interest

shares short against float, oldest to newest

Settlement	Of float	Shares short	Float	Avg volume
2026-10-30	1.08%	0.1M	6.4M	155.72K
2026-10-15	0.98%	0.1M	6.4M	262.58K

Option chain

expiry 2026-11-12

Type	Strike	Bid	Ask	Last	IV	Open int	Volume	Delta	Theta	Vega
No option chain for this symbol.

Type

Strike

Bid

Ask

Last

Open int

Volume

Delta

Theta

Vega

No option chain for this symbol.

Latest SEC filings

Filed	Form	Description	Period	Link
2026-11-04	4	Statement of changes in beneficial ownership of securities	2026-11-02	SEC
2026-11-04	3	Initial statement of beneficial ownership of securities	2026-11-02	SEC
2026-10-23	8-K	Current report	2026-10-21	SEC
2026-10-22	4	Statement of changes in beneficial ownership of securities	2026-10-22	SEC
2026-10-16	3	Initial statement of beneficial ownership of securities	2026-10-13	SEC
2026-10-16	SCHEDULE 13G			SEC
2026-10-16	SCHEDULE 13G			SEC
2026-10-15	SCHEDULE 13G			SEC
2026-10-14	SCHEDULE 13D			SEC
2026-10-13	4	Statement of changes in beneficial ownership of securities	2026-10-13	SEC
2026-10-13	4	Statement of changes in beneficial ownership of securities	2026-10-13	SEC
2026-10-13	4	Statement of changes in beneficial ownership of securities	2026-10-13	SEC
2026-10-13	4	Statement of changes in beneficial ownership of securities	2026-10-13	SEC
2026-10-13	4	Statement of changes in beneficial ownership of securities	2026-10-13	SEC
2026-10-13	4	Statement of changes in beneficial ownership of securities	2026-10-13	SEC
2026-10-13	4	Statement of changes in beneficial ownership of securities	2026-10-13	SEC
2026-10-13	3	Initial statement of beneficial ownership of securities	2026-10-13	SEC
2026-10-13	S-8	Initial registration statement for securities to be offered to employees pursuant to employee benefit plans		SEC
2026-10-13	8-K	Current report	2026-10-09	SEC
2026-10-09	424B4			SEC
2026-10-08	EFFECT	Effectiveness filing by commission order		SEC
2026-10-08	CERT			SEC
2026-10-08	4	Statement of changes in beneficial ownership of securities	2026-10-08	SEC
2026-10-08	4	Statement of changes in beneficial ownership of securities	2026-10-08	SEC
2026-10-08	4	Statement of changes in beneficial ownership of securities	2026-10-08	SEC
2026-10-08	S-1MEF	A new registration statement filed under Rule 462(b) to add securities to a prior related effective registration statement filed on Form S-1		SEC
2026-10-08	3	Initial statement of beneficial ownership of securities	2026-10-08	SEC
2026-10-08	3	Initial statement of beneficial ownership of securities	2026-10-08	SEC
2026-10-08	3	Initial statement of beneficial ownership of securities	2026-10-08	SEC
2026-10-08	3	Initial statement of beneficial ownership of securities	2026-10-08	SEC

Insider activity by month

Month	Bought	Buys
2026-11	0	0
2026-10	369.60K	2
2026-09	0	0
2026-08	0	0
2026-07	0	0
2026-06	0	0
2026-05	0	0
2026-04	0	0
2026-03	0	0
2026-02	0	0
2026-01	0	0
2025-12	0	0
2025-11	0	0

Institutional holders

Manager	% owned
-

Manager

% owned

Funds

Fund	% owned
-

Fund

% owned

OakChart. RTSN. Cached 15 minutes.

Some panels did not load: ratings, news.